Cure51 plans to analyze more than 1,000 tumor samples from exceptional cancer survivors PARIS, Oct. 31, 2024 /PRNewswire/ -- French…
GENEVA and BOSTONÂ Oct. 31, 2024 /PRNewswire/ -- FluoSphera, the leader in systemic drug discovery, is excited to announce its strategic…
BASKING RIDGE, N.J., Oct. 31, 2024 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA), a clinical-stage pharmaceutical company developing innovative…
LAWRENCEVILLE, N.J., Oct. 31, 2024 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage drug-development company focused on developing DNA-mediated…
Poster presentation at SITC to highlight extended follow-up data from AMPLIFY-7P Phase 1 study Oral presentation at SU2C Innovation Summit…
Trial builds upon promising evidence of clinical activity of TTX-080 when combined cetuximab, presented at ASCO 2024SOUTH SAN FRANCISCO, Calif.,…
Lung Cancer Awareness Month: Survivors Share Stories of Hope and Resilience Amid Revolutionary Medical BreakthroughsTORONTO, Oct. 31, 2024 (GLOBE NEWSWIRE)…
Phase 3 registrational trials evaluating petosemtamab in combination with pembrolizumab in 1L and petosemtamab monotherapy in 2/3L r/m HNSCC enrolling…
Company to host a conference call tomorrow at 8:00 a.m. ET NEWTON, Mass., Oct. 30, 2024 /PRNewswire/ -- Karyopharm Therapeutics…
"Discover High-Growth Opportunities Across Leading Sectors, With BCC Research Highlighting Industries Primed for Up to 20% Annual Returns" BOSTON, Oct.…